FAQ

insulin aspart, insulin aspart protamine drug combination 30:70

Known as: BIAsp 30, biphasic insulin aspart 30:70, biphasic insulin aspart 30 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2018
051019902018

Related topics

Related topics

5 relations

Broader (4)

Biphasic InsulinsHypoglycemic AgentsInsulin Aspartinsulin, isophane

Narrower (1)

NovoLog Mix 70/30

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
insulin aspart, insulin aspart protamine drug combination 30:70
insulin, isophane
Hypoglycemic Agents
Biphasic Insulins
Insulin Aspart
NovoLog Mix 70/30

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2013
2013
Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study
BACKGROUND The purpose of this study was to evaluate change in glycosylated hemoglobin (HbA1c), side effects, and quality of life… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2011
2011
Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70.
Postprandial hyperglycemia is known to be associated with increasing cardiovascular mortality in type 2 diabetes mellitus… (More)
Is this relevant?
2009
2009
Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE…
AIMS IMPROVE is an open-label, multinational, non-randomised, 26-week observational study designed to evaluate the safety and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2009
2009
Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
OBJECTIVES To estimate the cost-effectiveness of switching patients with poorly controlled type 2 diabetes mellitus from human… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2009
2009
Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the…
AIMS The IMPROVE observational study evaluated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30… (More)
Is this relevant?
2008
2008
The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.
AIMS The IMPROVE study is a multinational, open-label, non-randomised, 26-week observational study assessing the safety and… (More)
Is this relevant?
2008
2008
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
AIM The Physicians' Routine Evaluation of Safety and Efficacy of NovoMix 30 Therapy (PRESENT) study aims to assess the safety and… (More)
Is this relevant?
2007
2007
Basal insulin or premix analogue therapy in type 2 diabetes patients.
BACKGROUND We sought to compare the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) given twice daily with once… (More)
Is this relevant?
2003
2003
Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
OBJECTIVE Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine… (More)
Is this relevant?